Different β -Blockers in Patients With ST-segment Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

NCT04221919 NA UNKNOWN

Carvedilol, target dose: 50 mg daily; Bisoprolol, target dose: 10 mg daily; Metoprolol tartrate, target dose: 150 mg daily; Metroprolol succinate, target dose: 200 mg daily

Details

Lead sponsor	Qilu Hospital of Shandong University
Phase	NA
Status	UNKNOWN
Enrolment	1200
Start date	2020-01
Completion	2025-01

Conditions

• Primary PCI

Interventions

• β -Blockers

Primary outcomes

• Change in LVEDV from baseline — 1 to 5 years
  The primary outcome of this study will be the change from baseline in left ventricular end diastolic volume (LVEDV) post-PCI.
• Major adverse cardiovascular events (MACE) — 1 to 5 years